Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 18/20 | 1.00 |
| ▸ | PTGS2 | P35354 | 14/20 | 1.00 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.72 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31738526 | 1.00 | EPHX2 (1.00) | EPHX2PTGS2AKR1C3ALOX5 | |
| SCHEMBL9938572 | 0.92 | EPHX2 (1.00) | EPHX2PTGS2AKR1C3 | |
| SCHEMBL9939025 | 0.90 | EPHX2 (1.00) | EPHX2PTGS2AKR1C3ALOX5 | |
| SCHEMBL15460591 | 0.89 | EPHX2 (0.79) | EPHX2PTGS2AKR1C3ALOX5 | |
| SCHEMBL31738527 | 0.87 | EPHX2 (1.00) | EPHX2PTGS2AKR1C3 | |
| SCHEMBL9938907 | 0.87 | EPHX2 (1.00) | EPHX2PTGS2AKR1C3 | |
| SCHEMBL31738528 | 0.87 | EPHX2 (1.00) | EPHX2PTGS2AKR1C3ALOX5 | |
| SCHEMBL9938960 | 0.87 | EPHX2 (1.00) | EPHX2PTGS2AKR1C3ALOX5 | |
| SCHEMBL9979720 | 0.86 | EPHX2 (0.86) | EPHX2PTGS2AKR1C3 | |
| SCHEMBL9938619 | 0.84 | EPHX2 (1.00) | EPHX2PTGS2AKR1C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12485107-B2 | Methods for the prevention or treatment of cytokine storm | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2025-12-02 | — | — | US | claimed |
| US-11723929-B2 | Methods of improving cell-based therapy | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-08-15 | — | — | US | claimed |
| US-11426385-B2 | Methods of improving cancer chemotherapy | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-08-30 | — | — | US | claimed |
| US-20210145891-A1 | METHODS OF IMPROVING CELL-BASED THERAPY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2021-05-20 | — | — | US | claimed |
| WO-2019156991-A1 | METHODS OF INHIBITING FORMATION OF ALPHA SYNUCLEIN AGGREGATES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-08-15 | — | — | WO | claimed |
| WO-2018231702-A1 | METHODS OF IMPROVING CELL-BASED THERAPY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-12-20 | — | — | WO | claimed |
| US-12251379-B2 | Methods of inhibiting formation of alpha synuclein aggregates | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-03-18 | — | — | US | disclosed |
| US-20240024302-A1 | SOLUBLE EPOXIDE HYDROLASE (sEH) INHIBITORS AND DUAL COX/sEH INHIBITORS FOR THE TREATMENT OF ARRHYTHMOGENIC CARDIOMYOPATHY | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20240024302-A1 | SOLUBLE EPOXIDE HYDROLASE (sEH) INHIBITORS AND DUAL COX/sEH INHIBITORS FOR THE TREATMENT OF ARRHYTHMOGENIC CARDIOMYOPATHY | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 2024-01-25 | — | — | US | disclosed |
| WO-2023193010-A1 | METHODS OF IMPROVING CANCER IMMUNOTHERAPY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-10-05 | — | — | WO | disclosed |
| US-11723929-B2 | Methods of improving cell-based therapy | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-08-15 | — | — | US | disclosed |
| US-11426385-B2 | Methods of improving cancer chemotherapy | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-08-30 | — | — | US | disclosed |
| US-20220218667-A1 | DUAL INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE AND METHODS OF USE THEREOF | OROX BIOSCIENCES, INC. | 2022-07-14 | — | — | US | disclosed |
| US-9096532-B2 | Pyrazole inhibitors of COX-2 and sEH | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-08-04 | — | — | US | disclosed |
| US-9096532-B2 | Pyrazole inhibitors of COX-2 and sEH | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-08-04 | — | — | US | disclosed |
| US-20140038923-A1 | PYRAZOLE INHIBITORS OF COX-2 AND SEH | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-02-06 | — | — | US | disclosed |
| US-20140038923-A1 | PYRAZOLE INHIBITORS OF COX-2 AND SEH | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-02-06 | — | — | US | disclosed |
| US-20140038923-A1 | PYRAZOLE INHIBITORS OF COX-2 AND SEH | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-02-06 | — | — | US | disclosed |
| WO-2012082647-A2 | PYRAZOLE INHIBITORS OF COX-2 AND sEH | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-06-21 | — | — | WO | disclosed |
| WO-2012082647-A2 | PYRAZOLE INHIBITORS OF COX-2 AND sEH | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240024302-A1 | SOLUBLE EPOXIDE HYDROLASE (sEH) INHIBITORS AND DUAL COX/sEH INHIBITORS FOR THE TREATMENT OF ARRHYTHMOGENIC CARDIOMYOPATHY | EPHX1, EPHX2, PTGER1 | EPHX2 2/4885PTGS2 8/4885AKR1C3 141/4885 |
| US-11723929-B2 | Methods of improving cell-based therapy | EPHX1, EPHX2, NCEH1 | EPHX2 2/4885PTGS2 86/4885AKR1C3 2289/4885 |
| US-12251379-B2 | Methods of inhibiting formation of alpha synuclein aggregates | SNCA, PARK7, PYGB | EPHX2 3967/4885PTGS2 2366/4885AKR1C3 4621/4885 |
| US-20140038923-A1 | PYRAZOLE INHIBITORS OF COX-2 AND SEH | PTGES2, PTGS2, PTGES3 | EPHX2 5/4885PTGS2 2/4885AKR1C3 1894/4885 |
| US-12485107-B2 | Methods for the prevention or treatment of cytokine storm | TNF, PTGES2, IL2 | EPHX2 13/4885PTGS2 4/4885AKR1C3 902/4885 |
| US-11426385-B2 | Methods of improving cancer chemotherapy | ALOX5, EPHX1, ALOX12 | EPHX2 10/4885PTGS2 12/4885AKR1C3 747/4885 |
| US-20210145891-A1 | METHODS OF IMPROVING CELL-BASED THERAPY | EPHX1, EPHX2, NCEH1 | EPHX2 2/4885PTGS2 86/4885AKR1C3 2289/4885 |
| US-20220218667-A1 | DUAL INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE AND METHODS OF USE THEREOF | PTGES2, PTGS2, PTGES3 | EPHX2 4/4885PTGS2 2/4885AKR1C3 1110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.